The success of these drugs has validated Bcl-2 as a therapeutic target for cancer, however further studies into overcoming the resistance to cell death afforded by the expression of anti-apoptotic proteins in cancer cells is needed to develop additional therapeutics. The gene discussed is BCL2; the disease is cancer.